Study of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia (ITP)

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Initial Efficacy of CM313 (SC) Injection in Subjects With Primary Immune Thrombocytopenia

This is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and initial efficacy of CM313 (SC) injection in patients with primary immune thrombocytopenia.

Inclusion Criteria:

• 18 years old ≤ 75 years old, male or female.
• Fully understand and are able to comply with the requirements of the protocol and voluntarily sign the informed consent form.

Exclusion Criteria:

• Previously received allogeneic stem cell transplantation or organ transplantation.
• Laboratory abnormalities with clinical significance at screening visit.
• Pregnant or breastfeeding women, or women planning to become pregnant or breastfeeding during the study period; Male partners who plan to become pregnant during the study period.
• With any other situations that are not suitable for participation in this study by the investigator.